Bramlage, Carsten

[["dc.bibliographiccitation.firstpage","A100"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","MEDIZINISCHE KLINIK"],["dc.bibliographiccitation.lastpage","A101"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Scheel, A."],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Grone, H. J."],["dc.contributor.author","Mueller, Gerhard A."],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T09:59:01Z"],["dc.date.available","2018-11-07T09:59:01Z"],["dc.date.issued","2006"],["dc.identifier.isi","000237562000323"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37491"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.issn","0723-5003"],["dc.title","Effective therapy of a hepatitis-C-associated immunocomplex nephritis by means of cryoprecipitate apheresis and interferon-alpha"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","76"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","81"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Cuneo, A."],["dc.contributor.author","Haertel, D."],["dc.contributor.author","Jung, K."],["dc.contributor.author","Witteck, C.-H."],["dc.contributor.author","Hoegel, R."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Tebbe, Ulrich"],["dc.date.accessioned","2018-11-07T09:01:06Z"],["dc.date.available","2018-11-07T09:01:06Z"],["dc.date.issued","2011"],["dc.description.abstract","Background and objective: Angioplasty in patients with renal artery stenosis aims at reducing blood pressure and at improving kidney function. Its efficacy has however been questioned by recent published data. It was the aim of this retrospective study to compare angioplasty with medical treatment in an unselected patient population. Methods: Data on 109 patients were retrospectively anlysed. This cohort included all those patients admitted to the Lippe-Detmold Hospital between 1992 and 2008 for renal artery stenosis. The data included blood pressure, creatinine-based calculated glomerular filtration rate (cGFR), any renal dialysis, cardiovascular risk factors, events and survival time after transluminal renal angioplasty or drug treatment, respectively. Results: Patients who had undergone angioplasty were younger (p = 0.04), had less cardiovascular co-morbidity (p < 0.01), but a higher degree of stenosis (p < 0.01). After a median follow-up of 32.5 (angioplasty) and 36.0 months (drug treatment), respectively, a significant decrease of cGFR was recorded in drug treated patients (- 16.2 ml/min, 95%, CI - 25.7 to - 6.7) but not in the angioplasty group (- 4.5 ml/min, 95%, CI - 13.5 to 4.5). There were no other significant differences were not observed. Conclusion: Younger patients with a high degree of renal artery stenosis but without generalized atherosclerosis more frequently underwent angioplasty in clinical practice. The smaller post-angioplasty reduction in the loss of renal function in this group needs to be validated in a prospective, randomized study."],["dc.identifier.doi","10.1055/s-0030-1269442"],["dc.identifier.isi","000286135500002"],["dc.identifier.pmid","21225553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0012-0472"],["dc.title","Renal artery stenosis: angioplasty or drug treatment?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","855"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Der Urologe"],["dc.bibliographiccitation.lastpage","864"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Gross, O."],["dc.contributor.author","Bramlage, C."],["dc.date.accessioned","2020-12-10T14:08:40Z"],["dc.date.available","2020-12-10T14:08:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00120-018-0691-6"],["dc.identifier.eissn","1433-0563"],["dc.identifier.issn","0340-2592"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70517"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Nephrologie für Urologen"],["dc.title.alternative","Nephrology for urologists"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1215"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Mini Reviews in Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","1228"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Koziolek, M."],["dc.contributor.author","Vasko, R."],["dc.contributor.author","Bramlage, C."],["dc.contributor.author","Muller, G."],["dc.contributor.author","Strutz, F."],["dc.date.accessioned","2021-06-01T10:48:35Z"],["dc.date.available","2021-06-01T10:48:35Z"],["dc.date.issued","2009"],["dc.description.abstract","The chemokine CX3C-L/FKN is expressed in both soluble and transmembrane/mucin hybrid forms, thus combining chemoattractant functions together with receptor/adhesion molecule properties. In contrast to other chemokine receptors, CX3C-R is expressed not only on lymphoid cell populations, but also on several intrinsic cells including tubular epithelial cells and renal fibroblasts where it regulates various aspects of cell viability, matrix synthesis and degradation, migration, inflammation as well as oxidative stress. In the kidney, the chemokines/receptor pair has been shown to play a role in nephrogenesis as well as in the pathogenesis primary and secondary nephropathies. In several animal models and human specimens with acute and chronic renal failure including allograft nephropathy, CX3C-L/CX3C-R has been shown to exert immune and non-immune mediated renal damages. A blockade of this chemokine system ameliorated acute and chronic renal damages, though the latter to a more robust extent. There seems to a role of the CX3C-L/CX3C-R pair in mediating acute renal inflammation as well as in progressive chronic renal failure. However, functional studies are lacking for many aspects and further studies are necessary to better define the functional properties of CX3 C-L/FKN and its receptor."],["dc.identifier.doi","10.2174/138955709789055252"],["dc.identifier.isi","000271619500007"],["dc.identifier.pmid","19817712"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85989"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1389-5575"],["dc.title","The CX3C-Chemokine Fractalkine in Kidney Diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","833"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","MEDIZINISCHE KLINIK"],["dc.bibliographiccitation.lastpage","843"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Thoenes, Martin"],["dc.contributor.author","Paar, W. Dieter"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Schmieder, Roland E."],["dc.date.accessioned","2018-11-07T10:58:16Z"],["dc.date.available","2018-11-07T10:58:16Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: The transition of albumin from the vascular lumen into the surrounding tissue always indicates a serious disturbance of the vascular wall. Clinically, this process can be recognized as, cotton- wool\" spots of the retina or by testing the urine for the presence of albumin. The appearance of albumin in the urine is pathologic and should be evaluated within the context of the accompanying cardiovascular risk. Pathophysiology and Definitions: Albumin transition is indicative of a disturbance of the barrier function of endothelial cells. In the kidney, damage to podocytes, mesangial and endothelial cells, a loss of charge selectivity, and an altered expression of matrix proteins can be observed. However, vascular alterations are not confined to the kidney but can also be observed in the myocardium. Even though thresholds for microalbuminuria (> 30 mg/ 24 h) and proteinuria (> 300 mg/ 24 h) have been arbitrarily defined, an increase in risk starts at much lower levels of albumin excretion. Prevalence and Prognostic Importance: The prevalence of microalbuminuria in the general population is about 8%. However, prevalence rates of > 50% have been observed in high- risk groups, which are accompanied by an increased risk for cardiovascular morbidity and mortality. Therapeutic Options: A number of therapeutic options ( tight blood sugar control, blood pressure reduction, lipid lowering) lead to a reduction of albuminuria and an improvement in cardiovascular prognosis. This has particularly been described for renin- angiotensin- aldosterone system( RAAS-) blocking agents. Their use is not only associated with a reduced risk of end- organ damage ( heart failure, diabetic nephropathy, cerebrovascular events) but has been described to decrease mortality as well. Recommendation: A timely diagnosis, a consecutive cardiovascular diagnostic work- up and the subsequent use of RAAS- blocking agents is indicated in patients in whom albuminuria has been diagnosed."],["dc.identifier.doi","10.1007/s00063-007-1102-8"],["dc.identifier.isi","000250119500005"],["dc.identifier.pmid","17928967"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50439"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0723-5003"],["dc.title","Albuminuria: An indicator of cardiovascular risk"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S8"],["dc.bibliographiccitation.issue","46"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","S9"],["dc.bibliographiccitation.volume","132"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bevandaf, J."],["dc.contributor.author","Maatouk, I."],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Lauterberg, Christina"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T10:52:57Z"],["dc.date.available","2018-11-07T10:52:57Z"],["dc.date.issued","2007"],["dc.identifier.isi","000251423500025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49234"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.issn","0012-0472"],["dc.title","BMP-5 is expressed in renal interstitial fibroblasts and has TGF-beta neutralizing effect in vitro"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","401"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Scandinavian Journal of Rheumatology"],["dc.bibliographiccitation.lastpage","409"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Kaps, C."],["dc.contributor.author","Ungethuem, U."],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Wessels, Johannes Theodor"],["dc.contributor.author","Krenn, V."],["dc.contributor.author","Pruss, Axel"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Strutz, Frank M."],["dc.contributor.author","Burmester, Gerd-Ruediger"],["dc.contributor.author","Haeupl, T."],["dc.date.accessioned","2018-11-07T11:20:44Z"],["dc.date.available","2018-11-07T11:20:44Z"],["dc.date.issued","2008"],["dc.description.abstract","Objective: Growth differentiation factor-5 (GDF-5), a member of the transforming growth factor (TGF)-beta family, is involved in joint development during embryogenesis and has the potential to regenerate cartilage in adult animals. As progression of chronic joint diseases is influenced by cytokines of the synovial tissue, we examined the expression and effects of GDF-5 in this tissue. Methods: Microarray experiments were investigated for differential expression of GDF-5 in synovial tissues, synovial fibroblasts, and peripheral blood cells. GDF-5 expression was validated by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry, double immunofluorescence, and in situ hybridization in synovial tissue of normal donors (ND) and patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1 beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone. The influence of GDF-5 on macophages was studied by chemotaxis assay. Results: Microarray analysis and immunostaining revealed expression predominantly in synovial fibroblasts. Compared to patients without immunomodulating drugs, expression of GDF-5 was decreased significantly in patients receiving glucocorticoids and/or disease-modifying antirheumatic drugs (DMARDs) (p=0.007), but did not differ between the total group of ND, OA, and RA. Stimulation with prednisolone and TNF alpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1 beta revealed minor or no relevant change. GDF-5 also reduced cell migration of macrophages (p<0.001). Conclusion: GDF-5 is expressed in synovial fibroblasts and may counteract macrophage infiltration. Its modulation by inflammation and therapy suggests that glucocorticoids play a conflicting role by suppressing not only inflammation but also putative mechanisms of repair."],["dc.identifier.doi","10.1080/03009740802120010"],["dc.identifier.isi","000262270200001"],["dc.identifier.pmid","18830904"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55613"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis As"],["dc.relation.issn","0300-9742"],["dc.title","Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Hypertension"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Amann, Kerstin"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T11:14:45Z"],["dc.date.available","2018-11-07T11:14:45Z"],["dc.date.issued","2008"],["dc.format.extent","S154"],["dc.identifier.isi","000257197001070"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54209"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension"],["dc.relation.eventlocation","Berlin, GERMANY"],["dc.relation.issn","0263-6352"],["dc.title","The prenatal exposure of dexamethason in marmoset monkeys does not result in hypertension"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","142"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Transplantation Proceedings"],["dc.bibliographiccitation.lastpage","147"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Heeg, Malte"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Muehlhausen, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:30:22Z"],["dc.date.available","2018-11-07T09:30:22Z"],["dc.date.issued","2013"],["dc.description.abstract","Background. The most common immunosuppressive regimens after renal transplantation include calcineurin inhibitors (CNI). However, due to renal toxicity long-term graft survival does not seem to be positively affected by CNIs. Methods. In the present study, we investigated 17 patients, in which the CM immunosuppression was converted to a CM-free, mycophenolate sodium (MPS) regimen. Conversion was performed due to progressive impairment of the graft function from suspected CM toxicity. We retrospectively analyzed graft function as well as toxicity and surrogate markers for 4 years before and 4 years after conversion using a repeated-measures mixed model data analysis and/or a paired sample t-test. Results. The mean time point of therapy conversion was 11.2 +/- 4.6 years after transplantation. Within 1 month of CNI discontinuation, allograft function improved significantly, remaining at a significant level for 2 years. The estimated glomerular filtration rate increased from 43.4 +/- 14.8 to a maximum of 55.7 +/- 21.7 mL/min at 1 year after conversion (P = .0027). After 4 years, the end of the observation period, renal function was similar to the baseline. There were no significant side effects. Conclusion. These data suggested that, when chronic CM-toxicity is suspected, renal allograft recipients may benefit from CM withdrawal in favor of a MPS-including immunosuppressive regimen."],["dc.identifier.doi","10.1016/j.transproceed.2012.10.028"],["dc.identifier.isi","000315007200025"],["dc.identifier.pmid","23375288"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31288"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1873-2623"],["dc.relation.issn","0041-1345"],["dc.title","Improvement of Renal Graft Function After Conversion From a Calcineurin Inhibitor Including Immunosuppression to a Mycophenolate Sodium Including Regimen: A 4-year Follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","747"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Evaluation in Clinical Practice"],["dc.bibliographiccitation.lastpage","754"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Kröplin, Juliane"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Minguet, Joan"],["dc.contributor.author","Smith, Katherine Helen"],["dc.contributor.author","Lüders, Stephan"],["dc.contributor.author","Schrader, Joachim"],["dc.contributor.author","Patschan, Susan"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Deutsch, Cornelia"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Müller, Gerhard Anton"],["dc.contributor.author","Koziolek, Michael"],["dc.date.accessioned","2020-12-10T18:28:59Z"],["dc.date.available","2020-12-10T18:28:59Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/jep.12709"],["dc.identifier.issn","1356-1294"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76484"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Management of cardiovascular risk factors in patients with ANCA-associated vasculitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]